Jon P. Stonehouse - 01 Dec 2022 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role: President & CEO, Director
Signature: /s/ Alane P. Barnes, by power of attorney
Issuer symbol: BCRX
Transactions as of: 01 Dec 2022
Net transactions value: -$3,429,364
Form type: 4
Filing time: 02 Dec 2022, 17:33:59 UTC
Previous filing: 04 Jan 2023
Next filing: 19 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BCRX	Common Stock	Options Exercise	$305,182	+214,917	+24%	$1.42^*	1,116,747	01 Dec 2022	Direct	F1
transaction	BCRX	Common Stock	Sale	$2,793,921	-214,917	-19%	$13.00	901,830	01 Dec 2022	Direct	F1, F2
transaction	BCRX	Common Stock	Options Exercise	$117,372	+82,656	+9.2%	$1.42^*	984,486	02 Dec 2022	Direct	F1
transaction	BCRX	Common Stock	Sale	$1,057,997	-82,656	-8.4%	$12.80	901,830	02 Dec 2022	Direct	F1, F3
holding	BCRX	Common Stock						5,000	01 Dec 2022	By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust
holding	BCRX	Common Stock						5,000	01 Dec 2022	By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BCRX	Emp. Stock Option (Right to Buy)	Options Exercise	$0	-214,917	-72%	$0.000000	82,656	01 Dec 2022	Common Stock	214,917	$1.42	Direct	F1
transaction	BCRX	Emp. Stock Option (Right to Buy)	Options Exercise	$0	-82,656	-100%	$0.000000^*	0	02 Dec 2022	Common Stock	82,656	$1.42	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. The options were originally granted to the reporting person on January 1, 2013 and would have expired on January 1, 2023. The shares sold subsequent to the exercise of such options represent less than 10% of the reporting person's holdings of the issuer's securities.
F2	The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.75 to $13.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F3	The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.69 to $12.92. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.